FDA Seeks Input On How To Evaluate AI In Drug Development

FDA is seeking feedback from stakeholders on how to regulate the use of artificial intelligence (AI) and machine learning (ML) in drug development, with an aim to promote collaborative discussion as the number of submissions that involve the technologies increases. The release of the paper is one part of an ongoing FDA effort to increase stakeholder consultation on AI/ML and will be followed by workshops and other opportunities to engage with the agency on the topic, the agency says. “FDA...